INS and type 2 diabetes mellitus: Similarly, in Italy, the RESTORE study showed that 67.6% of insulin naïve patients with T2D on GLP-1 RA who need to intensifying therapy switched to BI (22.1% also starting 1–3 injections of short-acting analogues), 22.7% added BI while maintaining GLP-1 RA, and 9.7% switched to FRC, although effectiveness was improved with the add-on schemes [4].